Tumour lysis syndrome after treatment of chronic lymphocytic leukaemia with fludarabine.
Department of Internal Medicine, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain.
Fludarabine is one of the most recent and promising therapeutic agents for chronic lymphocytic leukaemia. We describe a patient who developed tumour lysis syndrome after the first course of treatment with fludarabine and call attention to this uncommon but potentially lethal complication that has not been previously taken into account in this neoplasia. It should always be anticipated when patients are treated with new and effective drugs.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Sewani, H. H., Rabatin, J. T.
(2002). Acute Tumor Lysis Syndrome in a Patient With Mixed Small Cell and Non-Small Cell Tumor. Mayo Clin Proc.
77: 722-728
[Abstract] -
Yeung, S.-C. J., Chiu, A. C., Vassilopoulou-Sellin, R., Gagel, R. F.
(1998). The Endocrine Effects of Nonhormonal Antineoplastic Therapy. Endocr. Rev.
19: 144-172
[Abstract] [Full Text]
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
